BCL2 and B-cell chronic lymphocytic leukemia: This compound inhibits Bcl-2 protein synthesis by inactivating Bcl-2 mRNA (Figure 5) and has shown chemosensitizing effects in combination with other conventional chemotherapeutic drugs, especially in chronic lymphocytic leukemia patients [118] (for a review see [113]).